2026-03-06T08:40:39Z https://repository.lib.tottori-u.ac.jp/oai

oai:repository.lib.tottori-u.ac.jp:02001568 2025-02-13T04:17:32Z 1:9 2:12

AMIGO2 expression as a predictor of recurrence in cervical cancer with intermediate risk Iida,Yuki Iida Yuki 15101 鳥取大学 Tottori University 40325006 尾崎,充彦 Osaki,Mitsuhiko オサキ,ミツヒコ 尾崎 Osaki オサキ 充彦 Mitsuhiko ミツヒコ 15101 鳥取大学 Tottori University 佐藤,慎也 Sato,Shinya サトウ,シンヤ 佐藤 Sato サトウ 慎也 Shinya シンヤ 15101 鳥取大学 Tottori University Izutsu,Runa Izutsu Runa 15101 鳥取大学 Tottori University Seong,Heekyung Seong Heekyung 15101 鳥取大学 Tottori University Okawa,Masayo Okawa Masayo 15101 鳥取大学 Tottori University Osaku,Daiken Osaku Daiken 15101 鳥取大学 Tottori University Komatsu,Hiroaki Komatsu Hiroaki 15101 鳥取大学 Tottori University 40322218 谷口,文紀 Taniguchi,Fuminori タニグチ,フミノリ 谷口 Taniguchi タニグチ 文紀 Fuminori フミノリ 15101 鳥取大学 Tottori University 250423 岡田,太 Okada,Futoshi オカダ,フトシ 岡田 Okada オカダ 太 Futoshi フトシ 15101 鳥取大学 Tottori University open access (C) 2023 Iida et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. AMIGO2 cervical cancer intermediate-risk group recurrence Patients with recurrent cervical cancer have limited treatment options and are often considered to be incurable. Since the expression of amphoterin-induced gene and open reading frame 2 (AMIGO2) in clinical samples is a prognostic factor for colorectal cancer and gastric cancer, the present aimed to elucidate whether it is also a prognostic factor for cervical cancer. Patients with primary cervical cancer who underwent radical hysterectomy or radical trachelectomy at our institution (Faculty of Medicine, Tottori University, Yonago, Japan) between September 2005 and October 2016 were retrospectively collected. Immunohistochemical analysis using a specific antibody against AMIGO2 was performed on 101 tumor samples, and the clinical characteristics, disease-free survival (DFS) and overall survival (OS) of the patients were examined. Patients in the AMIGO2-high group had a shorter 5-year DFS and OS than those in the AMIGO2-low group (P<0.001). Furthermore, AMIGO2 was an independent prognostic factor for DFS in multivariate analysis (P=0.0012). Patients in the AMIGO2-high group exhibited obvious recurrence compared with those in the AMIGO2-low group in the high-(P=0.03) and intermediate-risk groups (P=0.003). Positive lymph node metastasis, and parametrial, stromal and lymph vascular space invasion were significantly more common in AMIGO2-high patients. Taken together, AMIGO2 expression may be a predictive marker of recurrence for cervical cancer. In particular, it may be an indicator to determine the need for postoperative adjuvant therapy in intermediate-risk group patients. Spandidos Publications 2023-05-26 2023-05-26 eng journal article VoR https://repository.lib.tottori-u.ac.jp/records/2001568 https://doi.org/10.3892/mco.2023.2652 20499469 20499450 Molecular and clinical oncology Molecular and clinical oncology 19 19 1 1 56 56 https://repository.lib.tottori-u.ac.jp/record/2001568/files/mco19(1)_56.pdf application/pdf 4.4 MB 2023-05-26 2023-05-26